查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085863

體外診斷市場：2026-2032年全球市場預測（按設備類型、技術、配置、自動化程度、應用和最終用戶分類）

In-Vitro Diagnostics Instrument Market by Instrument Type, Technology, Configuration, Level Of Automation, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，體外診斷市場規模將達到 247.8 億美元，複合年成長率為 8.66%。

主要市場統計數據
基準年 2025 138.5億美元
預計年份：2026年 149.9億美元
預測年份 2032 247.8億美元
複合年成長率 (%) 8.66%

體外診斷（IVD）設備在現代醫學中發揮核心作用，它們將生物檢體轉化為臨床訊息，用於疾病檢測、治療方案選擇、後續觀察和公共衛生監督。該市場涵蓋免疫檢測分析儀、臨床化學系統、血液學平台、分子診斷儀器、血液凝固檢驗系統、自動化微生物設備、尿液檢查儀和即時檢測設備，廣泛應用於醫院、實驗室、血庫、診所和分散式醫療機構。

需求主要受已證實的醫療保健結構性趨勢所驅動，例如人口老化、慢性病負擔加重、持續感染疾病監測、抗生素抗藥性以及精準醫療的擴展。此外，檢查室整合、工作流程自動化、品質要求以及更嚴格的法律規範（例如美國FDA的體外診斷醫療器材框架和歐盟的體外診斷醫療設備法規（IVDR））也在推動產業成長。

體外診斷設備領域的變革性變化

體外診斷設備的發展趨勢正從關注檢測數量轉向整合、自動化以及與臨床環境的協同診斷。在檢查室中，高通量平台、隨機存取檢測、封閉式試管取樣、自動化樣本製備以及與實驗室資訊系統 (LIS) 的雙向連接正被優先考慮，以縮短週轉時間、確保可追溯性並提高可重複性。

人工智慧對體外診斷設備的累積影響

人工智慧 (AI) 正在透過改進影像解讀、最佳化檢測方法、預測性維護、工作流程調度、品管監控和決策支援整合，重塑體外診斷。 AI 驅動的數位病理學、血液學中的細胞形態學分析、微生物學中的菌落鑑定以及分子檢測結果解讀，在確保高通量檢查室一致性的同時，減輕了人工審核的負擔。

全球體外診斷市場的關鍵區域洞察

北美憑藉其先進的檢查室基礎設施、高昂的醫療費用支出、早期採用分子診斷技術以及完善的醫療必需檢測保險報銷機制，仍然是體外診斷領域的領先地區。美國透過參考實驗室、大學附屬醫院、FDA批准的診斷平台和精準醫療計畫推動創新，而加拿大則強調在其整個公共醫療保健網路中提供高品質的診斷服務。

關於東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體特定見解

東協地區的需求主要受醫院網路擴張、私人診斷市場成長以及政府改善感染疾病、孕產婦保健和非傳染性疾病檢測可及性的計畫所驅動。海灣合作理事會地區則以對三級醫療、大規模篩檢和數位醫療基礎設施的大量投資為特徵，尤其注重自動化、高階分析儀器、可靠的服務支援和互聯診斷。

主要體外診斷設備市場國別分析

美國在複雜度檢測、分子診斷、腫瘤伴隨診斷和檢查室自動化方面處於主導地位，這得益於其參考實驗室、醫院網路以及精準醫療的普及應用。加拿大優先在其省級醫療保健系統中推行標準化、品質保證的檢測，而墨西哥和巴西則正在擴大公立和私立診斷服務機構及實驗室在感染疾病、糖尿病、心血管疾病和腫瘤檢測方面的容量。

為體外診斷產業領導者提供的實用建議

產業領導者應優先考慮那些能夠兼顧分析準確性、自動化、連接性、網路安全和可擴展檢測範圍的平台。產品策略應同時滿足集中式高通量檢查室和分散式醫療機構的需求，並為醫院、參考實驗室、急診、門診部和即時檢測環境提供差異化的配置。

體外診斷設備市場分析的調查方法

本執行摘要採用結構化的研究途徑編寫，整合了二手研究、監管審查、行業標竿分析和證據三角檢驗。輸入資料包括來自世界衛生組織和美國疾病管制與預防中心等機構的公共衛生資料、來自美國食品藥物管理局和歐洲監管機構的法規結構、同行評審的臨床文獻、保險報銷情況、醫療基礎設施指標以及已發布的醫療衛生系統優先事項。

結論：體外診斷設備是精準醫療的基礎

體外診斷市場正進入一個臨床價值、自動化、人工智慧應對力、法規遵循和供應鏈韌性密不可分的新階段。設備評估不再僅基於檢測處理能力或檢測數量；買家越來越重視工作流程影響、資料整合、品質保證、服務可靠性、網路安全以及支援精準醫療和公共衛生應急能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 體外診斷設備市場：依設備類型分類

  • 化學分析儀
  • 凝血分析儀
  • 血液檢測設備
  • 免疫檢測分析儀
  • 微生物分析儀
  • 分子診斷
  • 照護現場

第8章 體外診斷設備市場：依技術分類

  • 層析法
    • 親和性和層析法
    • 氣相層析法
    • 離子交換層析法
    • 液相層析法
  • 細胞計量學
    • 流式細胞技術
    • 圖像細胞計數法
  • 免疫檢測
    • 化學冷光
    • 酵素免疫分析法（ELISA）
    • 螢光免疫分析
    • 濁度免疫檢測
  • 顯微鏡
    • 共聚焦顯微鏡
    • 電子顯微鏡
    • 光學顯微鏡
  • 分子
    • 雜合反應
    • 微陣列
    • 次世代定序
    • PCR
  • 光譜學
    • 螢光光譜法
    • 質譜分析
    • 紫外-可見光譜

第9章 體外診斷設備市場：依配置分類

  • 工作檯面
  • 落地式
  • 手持式
  • 可攜式的

第10章 體外診斷設備市場：依自動化程度分類

  • 手動的
  • 半自動
  • 全自動

第11章 體外診斷設備市場：依應用領域分類

  • 感染疾病
    • 呼吸道感染疾病
    • 性行為感染傳染病
    • 醫療相關感染疾病
  • 腫瘤學
    • 固體癌
    • 骨髓惡性腫瘤
  • 循環系統
    • 心臟標記物
    • 血脂檢測
  • 糖尿病
    • 血糖監測
    • 糖化血紅素 (HbA1c) 檢測
  • 自體免疫疾病
    • 自體抗體檢測
    • 發炎標記檢測
  • 腎臟病學
    • 腎功能檢查
    • 尿液化學成分
  • 女性健康
    • 產前篩檢
    • 不孕症檢查
  • 藥物篩檢
    • 藥物濫用檢測
    • 藥物監測

第12章 體外診斷設備市場：依最終用戶分類

  • 學術研究
  • 診斷檢查室
  • 醫院

第13章 體外診斷設備市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 體外診斷設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 體外診斷設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • A. Menarini Diagnostics Srl
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARKRAY, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • EKF GmbH
  • F. Hoffmann-La Roche Ltd
  • Fujirebio Holdings, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Mesolonghi Diagnostics
  • Mindray Medical International Limited
  • PerkinElmer, Inc.
  • PHC Corporation
  • Qiagen NV
  • Roche Diagnostics
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tulip Diagnostics（P）Ltd
Product Code: MRR-43127F7279FB

The In-Vitro Diagnostics Instrument Market is projected to grow by USD 24.78 billion at a CAGR of 8.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.85 billion
Estimated Year [2026] USD 14.99 billion
Forecast Year [2032] USD 24.78 billion
CAGR (%) 8.66%

In-vitro diagnostics (IVD) instruments are central to modern healthcare because they convert biological specimens into clinically actionable information for disease detection, therapy selection, monitoring, and public health surveillance. The market spans immunoassay analyzers, clinical chemistry systems, hematology platforms, molecular diagnostic instruments, coagulation systems, microbiology automation, urinalysis equipment, and point-of-care testing devices used across hospitals, reference laboratories, blood banks, physician offices, and decentralized care settings.

Demand is supported by verified structural healthcare trends: aging populations, a rising burden of chronic diseases, continuing infectious disease surveillance, antimicrobial resistance, and the expansion of precision medicine. Industry growth is also shaped by laboratory consolidation, workflow automation, quality requirements, and stricter regulatory oversight such as the U.S. FDA framework for IVDs and the European Union In Vitro Diagnostic Regulation (IVDR).

Transformative Shifts in the IVD Instrument Landscape

The IVD instrument landscape is shifting from volume-driven testing toward integrated, automated, and clinically connected diagnostics. Laboratories are prioritizing high-throughput platforms, random-access testing, closed-tube sampling, automated sample preparation, and bidirectional connectivity with laboratory information systems to reduce turnaround time, support traceability, and improve reproducibility.

Decentralized testing is another defining shift. Point-of-care molecular, immunoassay, and chemistry platforms are moving testing closer to emergency departments, outpatient clinics, pharmacies, and remote-care environments. At the same time, regulatory scrutiny, cybersecurity expectations, reagent supply resilience, service uptime, and interoperability standards are becoming strategic buying criteria alongside analytical performance and total cost of ownership.

Cumulative Impact of Artificial Intelligence on IVD Instruments

Artificial intelligence is reshaping IVD instruments by improving image interpretation, assay optimization, predictive maintenance, workflow scheduling, quality control monitoring, and decision-support integration. AI-enabled digital pathology, hematology cell morphology, microbiology colony reading, and molecular result interpretation can help reduce manual review burden while supporting consistency across high-volume laboratories.

The cumulative impact of AI is most powerful when algorithms are combined with validated datasets, quality management systems, and explainable clinical workflows. Adoption depends on regulatory validation, bias monitoring, cybersecurity, data governance, and integration into laboratory information systems. Leaders that treat AI as a regulated clinical capability rather than a stand-alone software feature will be better positioned to create durable value.

Key Regional Insights Across Global IVD Instrument Markets

North America remains a leading IVD instrument region due to advanced laboratory infrastructure, high healthcare spending, early adoption of molecular diagnostics, and established reimbursement pathways for medically necessary testing. The United States anchors innovation through reference laboratories, academic medical centers, FDA-cleared diagnostic platforms, and precision medicine programs, while Canada emphasizes quality-assured diagnostics across public healthcare networks.

Europe is shaped by the EU IVDR, which has increased the importance of clinical evidence, post-market surveillance, traceability, and conformity assessment. Germany, France, Italy, Spain, and the United Kingdom support demand through established hospital systems and cancer, cardiometabolic, antimicrobial resistance, and infectious disease testing needs. Asia-Pacific is the fastest-changing opportunity zone, led by China, India, Japan, South Korea, Australia, and ASEAN economies investing in laboratory capacity, local manufacturing, digital health infrastructure, and universal health coverage expansion.

Latin America, the Middle East, and Africa present diversified opportunities tied to infectious disease diagnostics, private healthcare investment, and public health modernization. Brazil and Mexico are major Latin American demand centers, GCC countries are investing in advanced hospitals, national screening programs, and connected laboratories, and African markets require scalable, robust instruments suited to fragmented infrastructure, high communicable disease burden, and expanding regional laboratory networks.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is driven by expanding hospital networks, rising private diagnostics, and government programs improving access to infectious disease, maternal health, and noncommunicable disease testing. The GCC is characterized by high investment in tertiary care, population screening, and digital health infrastructure, making automation, premium analyzers, reliable service support, and connected diagnostics especially relevant.

The European Union is defined by harmonized regulatory expectations under IVDR, making clinical evidence, traceability, post-market surveillance, and lifecycle compliance core supplier differentiators. BRICS countries represent large-volume opportunities due to population scale, chronic disease burden, tuberculosis and infectious disease surveillance, and local production priorities. G7 markets emphasize innovation, quality, reimbursement discipline, laboratory workforce efficiency, and AI-enabled automation, while NATO countries increasingly consider diagnostic resilience, supply security, and preparedness as part of broader health security planning.

Key Country Insights Across Major IVD Instrument Markets

The United States leads in high-complexity testing, molecular diagnostics, oncology companion diagnostics, and laboratory automation, supported by reference laboratories, hospital networks, and precision medicine adoption. Canada prioritizes standardized, quality-assured testing across provincial systems, while Mexico and Brazil are expanding private diagnostics and public laboratory capacity for infectious disease, diabetes, cardiovascular disease, and oncology testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain core demand centers for clinical chemistry, immunoassay, hematology, microbiology, and molecular platforms. Germany benefits from strong engineering and laboratory infrastructure, France and the United Kingdom emphasize public health and hospital modernization, while Italy and Spain continue investing in efficient diagnostics for aging populations. Russia maintains demand for domestic capacity and essential diagnostic platforms amid localization pressures.

China is scaling domestic IVD innovation and hospital testing capacity, India is expanding affordable diagnostics across urban and semi-urban settings, Japan prioritizes high-quality automated systems for an aging society, South Korea is strong in molecular diagnostics and export-oriented manufacturing, and Australia combines advanced reference laboratories with public health surveillance and decentralized access needs.

Actionable Recommendations for IVD Industry Leaders

Industry leaders should prioritize platforms that combine analytical accuracy, automation, connectivity, cybersecurity readiness, and scalable menu expansion. Product strategies should address both centralized high-throughput laboratories and decentralized care settings, with differentiated configurations for hospitals, reference labs, emergency departments, outpatient clinics, and point-of-care environments.

Manufacturers should strengthen regulatory intelligence, IVDR readiness, FDA submission planning, cybersecurity controls, quality management systems, and post-market evidence generation. Commercial teams should build value propositions around turnaround time, labor savings, uptime, reagent efficiency, total cost of ownership, and clinical impact. Partnerships with laboratories, health systems, AI developers, and regional distributors can accelerate adoption while improving localization, training, and service resilience.

Research Methodology for IVD Instrument Market Analysis

This executive summary is developed using a structured research approach that integrates secondary research, regulatory review, industry benchmarking, and evidence triangulation. Inputs include public health data from organizations such as WHO and CDC, regulatory frameworks from FDA and European authorities, peer-reviewed clinical literature, reimbursement context, healthcare infrastructure indicators, and published health system priorities.

The methodology evaluates demand drivers, instrument categories, end-user adoption, regional health priorities, competitive positioning, technology readiness, and policy developments. Insights are validated through cross-source comparison to avoid reliance on single-point assumptions. The analysis emphasizes evidence-backed trends, practical market implications, and commercially relevant opportunities for stakeholders across the IVD instrument value chain without using market sizing or forecasting claims.

Conclusion: IVD Instruments as a Foundation of Precision Healthcare

The in-vitro diagnostics instrument market is entering a phase where clinical value, automation, AI readiness, regulatory compliance, and supply resilience are inseparable. Instruments are no longer evaluated only by test throughput or menu size; buyers increasingly assess workflow impact, data integration, quality assurance, service reliability, cybersecurity, and the ability to support precision medicine and public health preparedness.

Organizations that invest in connected platforms, validated AI, decentralized testing models, robust quality systems, and region-specific commercialization strategies will be better positioned to support healthcare transformation. As healthcare systems pursue earlier diagnosis, faster treatment decisions, and more efficient laboratory operations, IVD instruments will remain foundational to evidence-based medicine worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. In-Vitro Diagnostics Instrument Market, by Instrument Type

  • 7.1. Chemistry Analyzer
  • 7.2. Coagulation Analyzer
  • 7.3. Hematology Analyzer
  • 7.4. Immunoassay Analyzer
  • 7.5. Microbiology Analyzer
  • 7.6. Molecular Diagnostics
  • 7.7. Point Of Care

8. In-Vitro Diagnostics Instrument Market, by Technology

  • 8.1. Chromatography
    • 8.1.1. Affinity Chromatography
    • 8.1.2. Gas Chromatography
    • 8.1.3. Ion Exchange Chromatography
    • 8.1.4. Liquid Chromatography
  • 8.2. Cytometry
    • 8.2.1. Flow Cytometry
    • 8.2.2. Image Cytometry
  • 8.3. Immunoassay
    • 8.3.1. Chemiluminescence
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Fluorescence Immunoassay
    • 8.3.4. Turbidimetric Immunoassay
  • 8.4. Microscopy
    • 8.4.1. Confocal Microscopy
    • 8.4.2. Electron Microscopy
    • 8.4.3. Light Microscopy
  • 8.5. Molecular
    • 8.5.1. Hybridization
    • 8.5.2. Microarray
    • 8.5.3. Next Generation Sequencing
    • 8.5.4. Pcr
  • 8.6. Spectrometry
    • 8.6.1. Fluorescence Spectroscopy
    • 8.6.2. Mass Spectrometry
    • 8.6.3. Uv Visible Spectroscopy

9. In-Vitro Diagnostics Instrument Market, by Configuration

  • 9.1. Benchtop
  • 9.2. Floor Standing
  • 9.3. Handheld
  • 9.4. Portable

10. In-Vitro Diagnostics Instrument Market, by Level Of Automation

  • 10.1. Manual
  • 10.2. Semi-Automated
  • 10.3. Fully Automated

11. In-Vitro Diagnostics Instrument Market, by Application

  • 11.1. Infectious Disease
    • 11.1.1. Respiratory Infections
    • 11.1.2. Sexually Transmitted Infections
    • 11.1.3. Healthcare-Associated Infections
  • 11.2. Oncology
    • 11.2.1. Solid Tumors
    • 11.2.2. Hematologic Malignancies
  • 11.3. Cardiology
    • 11.3.1. Cardiac Markers
    • 11.3.2. Lipid Testing
  • 11.4. Diabetes
    • 11.4.1. Glucose Monitoring
    • 11.4.2. HbA1c Testing
  • 11.5. Autoimmune Disease
    • 11.5.1. Autoantibody Testing
    • 11.5.2. Inflammatory Marker Testing
  • 11.6. Nephrology
    • 11.6.1. Renal Function Testing
    • 11.6.2. Urine Chemistry Testing
  • 11.7. Women's Health
    • 11.7.1. Prenatal Screening
    • 11.7.2. Fertility Testing
  • 11.8. Drug Screening
    • 11.8.1. Drugs Of Abuse Testing
    • 11.8.2. Therapeutic Drug Monitoring

12. In-Vitro Diagnostics Instrument Market, by End User

  • 12.1. Academic Research
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals

13. In-Vitro Diagnostics Instrument Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. In-Vitro Diagnostics Instrument Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. In-Vitro Diagnostics Instrument Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. A. Menarini Diagnostics S.r.l.
  • 17.2. Abbott Laboratories
  • 17.3. Agilent Technologies, Inc.
  • 17.4. ARKRAY, Inc.
  • 17.5. Becton, Dickinson and Company
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. BioMerieux S.A.
  • 17.8. Danaher Corporation
  • 17.9. DiaSorin S.p.A.
  • 17.10. EKF GmbH
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Fujirebio Holdings, Inc.
  • 17.13. Hologic, Inc.
  • 17.14. Illumina, Inc.
  • 17.15. Mesolonghi Diagnostics
  • 17.16. Mindray Medical International Limited
  • 17.17. PerkinElmer, Inc.
  • 17.18. PHC Corporation
  • 17.19. Qiagen N.V.
  • 17.20. Roche Diagnostics
  • 17.21. Seegene Inc.
  • 17.22. Siemens Healthineers AG
  • 17.23. Sysmex Corporation
  • 17.24. Thermo Fisher Scientific Inc.
  • 17.25. Tulip Diagnostics (P) Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMISTRY ANALYZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMISTRY ANALYZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMISTRY ANALYZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COAGULATION ANALYZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COAGULATION ANALYZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION ANALYZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGY ANALYZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGY ANALYZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGY ANALYZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOASSAY ANALYZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOASSAY ANALYZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOASSAY ANALYZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOLOGY ANALYZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOLOGY ANALYZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOLOGY ANALYZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AFFINITY CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AFFINITY CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AFFINITY CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GAS CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GAS CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GAS CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ION EXCHANGE CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ION EXCHANGE CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ION EXCHANGE CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIQUID CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMAGE CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGE CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMAGE CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TURBIDIMETRIC IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TURBIDIMETRIC IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TURBIDIMETRIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONFOCAL MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONFOCAL MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONFOCAL MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ELECTRON MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ELECTRON MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ELECTRON MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIGHT MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIGHT MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIGHT MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL FLUORESCENCE SPECTROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL FLUORESCENCE SPECTROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL FLUORESCENCE SPECTROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL UV VISIBLE SPECTROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL UV VISIBLE SPECTROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL UV VISIBLE SPECTROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BENCHTOP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BENCHTOP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BENCHTOP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL FLOOR STANDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL FLOOR STANDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL FLOOR STANDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HANDHELD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HANDHELD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HANDHELD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PORTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PORTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PORTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MANUAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MANUAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MANUAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SEMI-AUTOMATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SEMI-AUTOMATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SEMI-AUTOMATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL FULLY AUTOMATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL FULLY AUTOMATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL FULLY AUTOMATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HEALTHCARE-ASSOCIATED INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEALTHCARE-ASSOCIATED INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HEALTHCARE-ASSOCIATED INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL LIPID TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIPID TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL GLUCOSE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HBA1C TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HBA1C TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HBA1C TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL AUTOIMMUNE DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL AUTOIMMUNE DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL AUTOIMMUNE DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL AUTOANTIBODY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL AUTOANTIBODY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL AUTOANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL INFLAMMATORY MARKER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFLAMMATORY MARKER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL INFLAMMATORY MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEPHROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEPHROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEPHROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL RENAL FUNCTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL RENAL FUNCTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL RENAL FUNCTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL URINE CHEMISTRY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL URINE CHEMISTRY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL URINE CHEMISTRY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL WOMEN'S HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL WOMEN'S HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL WOMEN'S HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL PRENATAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL PRENATAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL PRENATAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL FERTILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL FERTILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL DRUGS OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUGS OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL DRUGS OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ACADEMIC RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ACADEMIC RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACADEMIC RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEPHROLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY WOMEN'S HEALTH, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DRUG SCREENING, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEPHROLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY WOMEN'S HEALTH, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DRUG SCREENING, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEPHROLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY WOMEN'S HEALTH, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DRUG SCREENING, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEPHROLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY WOMEN'S HEALTH, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DRUG SCREENING, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEPHROLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY WOMEN'S HEALTH, 2018-2032 (USD MILLION)
  • TABLE 316. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DRUG SCREENING, 2018-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 326. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 327. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 328. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 329. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 331. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 332. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 334. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 335. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY NEPHROLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY WOMEN'S HEALTH, 2018-2032 (USD MILLION)
  • TABLE 337. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY DRUG SCREENING, 2018-2032 (USD MILLION)
  • TABLE 338. AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 344. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 345. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 346. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MICROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 347. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 348. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 349. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CONFIGURATION, 2018-2032 (USD MILLION)
  • TABLE 350. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY LEVEL OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 351. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 352. ASEAN IN-VITRO DIAGNOSTICS INSTRUMENT MARK